Circulating serologic and molecular biomarkers in malignant melanoma

Shanique R. Palmer, Lori A. Erickson, Ilia Ichetovkin, Daniel J. Knauer, Svetomir Nenad Markovic

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The worldwide incidence of malignant melanoma has been increasing during the past decade and is a public health concern because this disease accounts for up to 90% of deaths from cutaneous malignancies. It remains a devastating disease with few therapeutic options once in an advanced stage. Current methods of detection, prognostication, and monitoring of melanoma focus on clinical, morphologic, and histopathologic characteristics of measurable tumor. Although this information provides some insight into disease behavior and outcome, melanoma is still an unpredictable disease. Significant effort has been put into finding an informative serologic biomarker. However, the marker remains elusive, and investigations continue. Using the PubMed database, we reviewed the published literature on serologic melanoma biomarkers and present a synopsis of the extensive investigations that have been performed thus far, provide some insight into why most have failed to become incorporated into routine clinical use, and present an overview of innovative methods currently being explored.

Original languageEnglish (US)
Pages (from-to)981-990
Number of pages10
JournalMayo Clinic Proceedings
Volume86
Issue number10
DOIs
StatePublished - 2011

Fingerprint

Melanoma
Biomarkers
PubMed
Neoplasms
Public Health
Databases
Skin
Incidence
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Circulating serologic and molecular biomarkers in malignant melanoma. / Palmer, Shanique R.; Erickson, Lori A.; Ichetovkin, Ilia; Knauer, Daniel J.; Markovic, Svetomir Nenad.

In: Mayo Clinic Proceedings, Vol. 86, No. 10, 2011, p. 981-990.

Research output: Contribution to journalArticle

Palmer, Shanique R. ; Erickson, Lori A. ; Ichetovkin, Ilia ; Knauer, Daniel J. ; Markovic, Svetomir Nenad. / Circulating serologic and molecular biomarkers in malignant melanoma. In: Mayo Clinic Proceedings. 2011 ; Vol. 86, No. 10. pp. 981-990.
@article{ed5d49eb0b364b52b8fc723a93cbbf6d,
title = "Circulating serologic and molecular biomarkers in malignant melanoma",
abstract = "The worldwide incidence of malignant melanoma has been increasing during the past decade and is a public health concern because this disease accounts for up to 90{\%} of deaths from cutaneous malignancies. It remains a devastating disease with few therapeutic options once in an advanced stage. Current methods of detection, prognostication, and monitoring of melanoma focus on clinical, morphologic, and histopathologic characteristics of measurable tumor. Although this information provides some insight into disease behavior and outcome, melanoma is still an unpredictable disease. Significant effort has been put into finding an informative serologic biomarker. However, the marker remains elusive, and investigations continue. Using the PubMed database, we reviewed the published literature on serologic melanoma biomarkers and present a synopsis of the extensive investigations that have been performed thus far, provide some insight into why most have failed to become incorporated into routine clinical use, and present an overview of innovative methods currently being explored.",
author = "Palmer, {Shanique R.} and Erickson, {Lori A.} and Ilia Ichetovkin and Knauer, {Daniel J.} and Markovic, {Svetomir Nenad}",
year = "2011",
doi = "10.4065/mcp.2011.0287",
language = "English (US)",
volume = "86",
pages = "981--990",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "10",

}

TY - JOUR

T1 - Circulating serologic and molecular biomarkers in malignant melanoma

AU - Palmer, Shanique R.

AU - Erickson, Lori A.

AU - Ichetovkin, Ilia

AU - Knauer, Daniel J.

AU - Markovic, Svetomir Nenad

PY - 2011

Y1 - 2011

N2 - The worldwide incidence of malignant melanoma has been increasing during the past decade and is a public health concern because this disease accounts for up to 90% of deaths from cutaneous malignancies. It remains a devastating disease with few therapeutic options once in an advanced stage. Current methods of detection, prognostication, and monitoring of melanoma focus on clinical, morphologic, and histopathologic characteristics of measurable tumor. Although this information provides some insight into disease behavior and outcome, melanoma is still an unpredictable disease. Significant effort has been put into finding an informative serologic biomarker. However, the marker remains elusive, and investigations continue. Using the PubMed database, we reviewed the published literature on serologic melanoma biomarkers and present a synopsis of the extensive investigations that have been performed thus far, provide some insight into why most have failed to become incorporated into routine clinical use, and present an overview of innovative methods currently being explored.

AB - The worldwide incidence of malignant melanoma has been increasing during the past decade and is a public health concern because this disease accounts for up to 90% of deaths from cutaneous malignancies. It remains a devastating disease with few therapeutic options once in an advanced stage. Current methods of detection, prognostication, and monitoring of melanoma focus on clinical, morphologic, and histopathologic characteristics of measurable tumor. Although this information provides some insight into disease behavior and outcome, melanoma is still an unpredictable disease. Significant effort has been put into finding an informative serologic biomarker. However, the marker remains elusive, and investigations continue. Using the PubMed database, we reviewed the published literature on serologic melanoma biomarkers and present a synopsis of the extensive investigations that have been performed thus far, provide some insight into why most have failed to become incorporated into routine clinical use, and present an overview of innovative methods currently being explored.

UR - http://www.scopus.com/inward/record.url?scp=80053478911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053478911&partnerID=8YFLogxK

U2 - 10.4065/mcp.2011.0287

DO - 10.4065/mcp.2011.0287

M3 - Article

VL - 86

SP - 981

EP - 990

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 10

ER -